New smart insulin pump shows promise for diabetes control
NCT ID NCT06547918
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the safety and effectiveness of the Omnipod 5 SmartAdjust 2.0 system, an automated insulin pump, in 48 people aged 2 to 70 with type 1 or type 2 diabetes. The system uses a continuous glucose monitor to automatically adjust insulin delivery. The main goals were to see how well it keeps blood sugar from going too low or too high.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Otago, Christchurch
Christchurch, 8011, New Zealand
-
Wellington Regional Hospital
Wellington, 6021, New Zealand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personality type may influence diabetic wound healing – a study investigates
- Quitting smoking may also ward off diabetes — a trial puts the dual strategy to the test
- Could a simple clinic Check-In change catch hidden high blood pressure and diabetes?
- Can a strong support network help people with diabetic kidney disease take better care of themselves?
- Eye scan may spot hidden blood-flow changes that signal glaucoma risk in diabetes
- Tight glucose control may preserve insulin-making cells in type 2 diabetes